At the 49th Congress of the International Society of Paediatric Oncology held in Washington D.C., October 12-15, Rare Disease Report spoke with Kristin Knight, MS, CCC-A, Associate Professor of Pediatrics at the School of Medicine, Oregon Health and Science University in Portland, Oregon about the long-term outcomes of ototoxicity in families with children who underwent cisplatin therapy for pediatric cancer and are developing hearing loss.
Knight is a leading audiologist and her study comparing different methods to best measure ototoxicity in children receiving cisplatin-based chemotherapy showed that the SIOP-Boston Ototoxicity Scale seems to be the most favorable method.
Knight KR, Chen L, Freyer D, et al. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol. 2017;35:440-445.